Goldman Sachs Upgrades Beta Bionics (BBNX) to Buy, Raises PT to $26 on Strong Growth and Market Outlook

Beta Bionics Inc. (NASDAQ:BBNX) is a top stock pick with strong growth potential. Goldman Sachs upgraded the company with a $26 price target. Beta Bionics reported a 54% increase in net sales and raised its full-year guidance.